Our objective is to investigate the utility of denoising thin section CT image data to improve the classification of scleroderma disease patterns. The patterns are lung fibrosis (LF), groundglass ...

Scleroderma is classified as a rare, autoimmune, collagen-vascular disease of unknown etiology that can be difficult to diagnose and treat. Its onset can be insidious or rapid; the symptoms range ...

Scleroderma was more common on fingers and hands than on any other part of the ... Conclusions The EUSTAR database provides an abundance of information on the true clinical face of SSc that will be ...

1 Department of Rheumatology and Immunology, Qinzhou First People's Hospital, Qinzhou, Guangxi, China 2 Minda Hospital of Hubei Minzu University, Enshi, China Cell therapy is an emerging strategy for ...

The classification system was reduced by clustering items and simplifying weights. The system was tested by (1) determining specificity and sensitivity in SSc cases and controls with scleroderma-like ...

The classification of a production area determines the treatment required before Live Bivalve Molluscs (shellfish) may be marketed for human consumption. Shellfish production and relay areas are ...

TRANS/WP.29/1045 - Special Resolution No. 1 concerning the common definitions of vehicle categories, masses and dimensions (S.R.1) ...

Diamond “type” is a concept that is frequently mentioned in the gemological literature, but its relevance to the practicing gemologist is rarely discussed. Diamonds are broadly divided into two types ...

Anifrolumab is under clinical development by AstraZeneca and currently in Phase III for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase III drugs for Systemic Sclerosis (Scleroderma) ...

Truffles are all the rage right now, but they're pricy and rare. Use this guide to learn to avoid fake and false truffles, ...

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis ...